AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Tagrisso (osimertinib) by Quarter
Tagrisso (osimertinib) — Emerging Markets YoY CER (%) (%)
AstraZeneca Tagrisso (osimertinib): 1.0% in Q2 2026, down 14.0 pts from a year earlier.
Latest, Q2 2026
1.0%
Period ended Jun 30, 2026
Change on a year earlier
-14.0 pts
15.0% in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below
Where the Q2 2026 figure comes from
“|| Tagrisso | 1,941 | | 7 | | 6 | | 845 | | 11 | | 512 | | 5 | | 1 | | 383 | | 9 | | 4 | | 201 | | ( 3 ) | | 2”
Source: Form 6-K FY2026Q2 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AstraZeneca Tagrisso (osimertinib) (%), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-tagrisso-em-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.